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Abstract
Despite the potential for protection against a broad spectrum of pathogens, the availability of an increased number of effective vaccines could
lead to a signiﬁcant reduction in vaccination coverage as the result of issues with implementation of new vaccines within existing protocols. To
overcome these problems, the development of combined vaccines has been promoted. The use of combined vaccines offers a number of
potential beneﬁts, including a reduction in the number of patient visits, reduced complications associated with multiple intramuscular
injections, decreased costs of stocking and administering separate vaccines, and a lowering of the risk of delayed or missed vaccinations. The
hexavalent vaccine includes antigens against diphtheria, tetanus, acellular pertussis (DTaP), hepatitis B (HBsAg), poliomyelitis (P1, P2, P3) and
Haemophilus inﬂuenzae type B (Hib) infections. The primary goal of this review is to discuss the immunogenicity, efﬁcacy, safety and tolerability
of several hexavalent preparations that are either commercially available or still under development.
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Introduction
Over the last 20 years a signiﬁcant number of new effective
vaccines against infectious diseases have become available. Most
of these have been adoptedworldwide for use in children, with a
relevant increase in the complexity of paediatric immunization
schedules [1]. However, these regimens also increase the
number of injections administered in a single visit, leading many
immunization providers and parents to refuse one or more
immunizations because of the child’s fear of needles [2] and pain
[3–7] in addition to a number of unsubstantiated concerns
regarding safety [8,9]. Consequently, the availability of more
vaccines could lead to a signiﬁcant reduction in vaccination
coverage through greater difﬁculties in implementing pro-
grammes for new vaccines. To overcome these issues, the
development of combined vaccines was promoted. The use of
combined vaccines, which include several antigens in a single
administration, have a number of potential beneﬁts including a
reduction in the number of visits and complications related to
multiple intramuscular injections, decreased costs of stocking
and administering separate vaccines, and reduced risk of delayed
or missed vaccinations [10]. The combined diphtheria, tetanus
and pertussis vaccine, which includes a whole cell pertussis
component (DTwP) or two or more pertussis antigens (DTaP),
has already been incorporated into the national immunization
schedules of several countries worldwide. This served as the
core formulation to which other vaccines were added. To gain
acceptance by health authorities, combination products had to
demonstrate that their use was not associated with any
signiﬁcant decrease in immunogenicity or efﬁcacy, or increase
in reactogenicity with any component compared with the
individual vaccine given separately [11].
One formulation known as the hexavalent vaccine combines
DTaP with antigens against hepatitis B (HBsAg), poliomyelitis
(P1, P2, P3) and Haemophilus inﬂuenzae type B (Hib) infection. A
number of similar but not identical hexavalent preparations have
been developed by pharmaceutical companies. The primary goal
of this review is to discuss the immunogenicity, efﬁcacy, safety
and tolerability of several hexavalent preparations that are
either commercially available or still under development.
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Hexavac
Hexavac (Sanoﬁ Pasteur MSD, Lyon, France) was licensed in
Europe in October 2000 as a paediatric primary and booster
immunization and is widely used in many European countries.
One single dose is composed of D toxoid (≥20 IU), T toxoid
(≥40 IU), pertussis toxoid (PT) (25 lg), pertussis ﬁlamentous
haemagglutinin (FHA) (25 lg), HBsAg (produced from recom-
binant strain of the yeast Saccharromyces cerevisiae) (5.0 lg), P1
(Mahoney strain) (40 DAU), P2 (MEF 1 strain) (8 DAU), P3
(Saukett strain) (32 DAU) and Hib (polyribosylribitol phos-
phate) 12 lg conjugated to tetanus toxoid (24 lg). Several
comparative, controlled clinical trials deemed Hexavac to be
very effective in assuring long-term protection against all of the
indicated target diseases with a high degree of safety and
tolerance. It was also deemed non-inferior or equivalent to
comparator vaccines, including both separate vaccine compo-
nents and Infanrix hexa, the second hexavalent vaccine available
in this time period [12]. However, in September 2005 the
European Medicines Agency recommended suspension of
Hexavac marketing authorization because of the reduced
immunization properties of the hepatitis B virus (HBV)
component [13]. In particular, it was found that although
>95% of children vaccinated with Hexavac seroconverted and
had protective antibody concentrations (≥10 IU/L) 1 month
after primary immunization, 5–20% of them had relatively low
antibody titres (≤100 IU/L) [14–16]. Moreover, these children
had a signiﬁcantly diminished response to a subsequent booster
dose compared with children with greater antibody titres after
the primary series [14–16]. Data conﬁrming the low
immunogenicity of the hepatitis B component of Hexavac were
further collected when this vaccine was administered in
conjunction with the heptavalent pneumococcal conjugate
vaccine (PCV7) or with the meningococcal type C conjugate
vaccine. In both cases, vaccinated children had lower than
expected anti-HB seroconversion rates and antibody geometric
mean titres (GMTs) [16,17]. Because peak antibody levels
achieved after primary and booster immunizations condition the
length of the period during which concentrations remain within
the protective range, it was assumed that in a proportion of
children immunized with Hexavac the vaccine might not have
assured protection against hepatitis B during adolescence and
adulthood. Consequently, the vaccine lost authorization for use
in children and was withdrawn from the market. Moreover,
although the European Medicines Agency did not mandate the
immediate revaccination of children that had received Hexavac,
some health authorities recommended the administration of a
booster dose of hepatitis B vaccine to ensure long-term
adequate protection [18].
However, further studies have clariﬁed the characteristics
of the immune response evoked by the hepatitis B compo-
nent of Hexavac, apparently reducing the importance of its
lower antibody production for children in the ﬁrst years of
life. Initial surveillance studies did not report evidence of
breakthrough HBV infections in children vaccinated with
Hexavac. In Italy, a country where this vaccine was largely
used, no case was reported between 2000 and 2009, i.e. at
least 3–4 years after the last vaccine dose [19]. Moreover, it
was demonstrated that in healthy vaccinated children the
immunological memory for HBsAg might persist regardless of
the presence of protective antibodies, providing effective
protection even in those showing waning or undetectable
concentrations of anti-HBs after primary vaccination [19–21].
In the study carried out by Zanetti et al., which included 831
children 5–6 years old who had received Hexavac at 3, 5 and
11–12 months of age. The study noted that despite the fact
that over 60% of them did not have protective anti-HBs
concentrations at the moment of administration of the
booster dose, a protective antibody response (≥10 IU/L) was
evoked in 92.1% of study participants [21]. This was
considered the best evidence that even in the absence of
protective antibody levels, children who had received Hexa-
vac maintained T-cell memory and were able to trigger
anti-HBs production by B cells when exposed to the viral
antigen. The study concluded that because hepatitis B has a
long incubation period, the effective immune memory of
primed children assures the possibility of developing adequate
protection against acute disease and the development of a
chronic carrier state, independent of the antibody level [21].
Consequently, a booster dose of hepatitis B vaccine was
considered not mandatory in immunocompetent participants
who were given Hexavac [21]. However, a recent
meta-analysis of studies that have evaluated the persistence
of protection after hepatitis B vaccination identiﬁed maternal
carrier status (OR 2.37; 95% CI 1.11–5.08), administration of
a lower vaccine dosage than presently recommended (OR
0.14; 95% CI 0.06–0.30) and the gap time between the last
and preceding doses of the primary vaccine series (OR 0.44;
95% CI 0.22–0.86) as determinants for persistence of
anti-HBsAg antibodies ≥10 IU/L [22]. A lower vaccine dosage
was also associated with failure to respond to booster (OR
0.20; 95% CI 0.10–0.38) [22]. Because Hexavac HBsAg
content was only 5 lg, the possibility that children who
received this vaccine could be at higher risk of losing immune
memory and developing infections of HBV in adolescence or
in adulthood cannot be excluded. On the other hand, recent
studies showed that immune memory may diminish during
the second decade post-vaccination (particularly in children
vaccinated at birth), suggesting the need for a booster dose
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during adolescence [23–25]. Wu et al [26] showed that 15%
of adolescents born to HBsAg/HBeAg-positive mothers who
received primary infantile vaccination developed chronic HBV
infection. In addition, one in six vaccine recipients were
unable to respond to booster vaccination, having lost
immunological memory [26].
Further doubts about the use of Hexavac were raised when
a possible association between immunization with this vaccine
and the occurrence of sudden unexpected death (SUD) was
suspected [27]. Three SUDs occurred in Germany between
November 2000 and June 2003 in toddlers within 48 h after the
administration of the booster dose of the vaccine. No signal
was detected for doses given during the ﬁrst year of life.
Standardized mortality ratios for SUD cases within 1 day of
vaccination were 31.3 (95% CI 3.8–113.1; two cases observed;
0.06 cases expected) and 23.5 within 2 days after vaccination
(95% CI 4.8–68,6; three cases observed; 0.13 cases expected).
Despite the fact that these data did not prove a causal
relationship between vaccination and SUD, they were consid-
ered the basis for the need for intensifying surveillance. In
contrast, an Italian case series study including c.95% of 3.2
million neonates born in the period 1999–2004 reported that
the association between hexavalent vaccine administration and
risk of SUD in the ﬁrst 14 days after vaccine administration was
signiﬁcantly lower than that estimated in Germany (relative risk
1.5) and was limited to the ﬁrst vaccine dose, at an age when the
incidence of SUD is also the highest. Relative risk in the ﬁrst
2 days after vaccination was 0.7 and 2.3 for Hexavac and
Infanrix hexa, respectively, whereas it was 2.8 versus 1.4 and
1.6 versus 1.5 for the ﬁrst week and for the 2 weeks after
vaccine administration [28]. Starting from these data, it was
concluded that the limited increase in relative risk appeared to
be conﬁned to the ﬁrst dose and may be partially explained by
the confounding effect of age.
In conclusion, although the problems of poor immunoge-
nicity of hepatitis B vaccines and the need for a booster dose
during adolescence are still debated, Hexavac was the
hexavalent vaccine with which the greatest problems devel-
oped; this seems sufﬁcient to justify the decision of the
European Medicines Agency. This explains why the vaccine was
abandoned and its producers shifted towards the development
of a new hexavalent preparation.
Infanrix Hexa
Licensed as Hexavac in 2000, Infanrix (GSK, Riixensart,
Belgium) hexa is the only hexavalent vaccine authorized for
paediatric use in Europe. Its composition is similar to that of
Hexavac with two main exceptions. In addition to the pertussis
antigens PT and FHA, pertactin (PRN 8 lg) is also included.
HBsAg is present in a doubled amount, 10 lg instead of 5 lg.
Additionally, unlike Hexavac, Hib antigen needs to be recon-
stituted before use.
Several studies have evaluated the immunogenicity, safety and
tolerability of this vaccine after primary immunization (two or
three doses in the ﬁrst 6 months of age according to the
schedules recommended for infants) and after a booster dose at
12–15 months of age in comparison with several DTaP-based
pentavalent vaccines administered in conjunction with mono-
valent HBV or Hib vaccines. Several studies have also compared
Infanrix hexa with Hexavac [29]. Evaluation of immunogenicity
was performed on blood samples drawn 1 month after the last
primary series dose and 1 month after the booster administra-
tion. Antibody concentrations against D and T toxoids of
≥0.1 IU/mL, HBsAg of ≥10 IU/L, polyribosylribitol phosphate
polysaccharide (PRP) of ≥0.15 mg/mL and/or ≥1 mg/mL (mark-
ers of short-term and long-term protective immunity, respec-
tively) and against P1, P2 and P3 antigens of ≥1 : 8 were
considered the cut-off values to evaluate seroconversion and
seroprotection rates [30]. Moreover, because no generally
accepted seroprotective antibody levels for pertussis antigens
were established, vaccine seroresponse/seropositivity rates
against PT, FHA and PRN were assessed and vaccine response
was deﬁned as the proportion of patients with post-vaccination
antibody titres of ≥5 U/mL in initially seronegative infants and
minimalmaintenance of pre-vaccination antibody titres in infants
who were seropositive before vaccination (i.e. titres ≥5 U/mL).
Seropositivity rates were deﬁned as the proportion of infants
with antibody titres ≥5 U/mL.
Throughout all of the studies evaluating an immune response
it was demonstrated that all components of Infanrix hexa were
highly immunogenic and equivalent or non-inferior to compar-
ators (Fig. 1) [31–37]. In particular, seroprotective antibody
concentrations against D, T, P1, P2 and P3 were achieved in
≥95% of children after primary series and in ≥99% after booster
dose compared with ≥94% and 100% of the children who
received comparators [31–37]. Seroprotectionwas still found in
most of the children before the booster dose and this evoked a
strong immune response, independently from the schedule and
the type of vaccine used for primary immunization. Similar data
were reported for the three P antigens. Response rates against
PT, FHA and PRN were ≥95% and ≥86%, after primary
vaccination and booster dose, respectively, compared with
≥90% and 100% of the children who were given comparator
vaccines [30–36]. Short-term protection against Hib was
observed in ≥93% and in ≥98% of children who were treated
with Infanrix hexa after primary series and booster dose,
respectively, in comparison to ≥92% and 100% of infants who
received comparator vaccines. Antibody concentrations
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suggestive of long-term protection against this pathogen were
achieved in ≥62% and ≥98% of children included in the Infanrix
hexa group after primary and booster vaccination, respectively,
whereas children who received comparators were protected in
≥66% and ≥97% of the cases. Finally, a strong immune response
against HBsAg was observed. Seroprotective antibody concen-
trationswere found in ≥96%of infants after primary series and in
≥98% after booster dose compared with ≥82% and 100% of
children who received comparators, irrespective of the vacci-
nation schedule [31–37]. A strong immune response against
Infanrix hexa antigens after primary vaccination and booster
dose was also evoked in children who were given a dose of
hepatitis B vaccine at birth [38,39] as well as in preterm infants
[40–42]. Finally, co-administration with other vaccines did not
modify the immunogenicity of Infanrix hexa. This was demon-
strated with pneumococcal conjugate vaccines, independently
from the number of pneumococcal serotypes included in these
preparations [43–47], with meningococcal conjugate vaccines,
both with preparations including serogroup C [48,49] and with
that against serogroups A, C, W135 and Y [50], with measles,
mumps, rubella and varicella vaccine [51] and with rotavirus
vaccine [52].
Protection evoked by Infanrix hexa was found to persist in
the long term (Table 1). In the study carried out by Zinke et al.
FIG. 1. Immune response evoked by
Infanrix hexa in children 15–18 months
of age after a booster dose in comparison
to Infanrix IPV Hib + HBV. Adapted from
Heininger et al. [37].
Subjects seroprotected/seropositive, %
Antigen
Diphtheria 96 86 >98a
Tetanus 74 64  100a
PT 25 32 >60a
FHA >95a 98  100a
PRN >85a 87  100a
Polio type 1 >95 91  100a
Polio type 2 >95 91  100a
Polio type 3 >95 97 100a
HBsAg 86 77 Not tested
Hib-PRP
aExact numbers not quoted.
FHA, filamentous haemagglutinin; HBsAg, hepatitis B surface antigen; Hib, H. influenzae
type b; PRN, pertactin; PRP, polyribosylribitol phophate; PT, pertussis toxoid.
>95 99 Not tested
Children 4–6 years of
age
Children 7–9 years of
age (not boosted)
Children 7–9 years of
age (boosted)
TABLE 1. Seroprotection/seropositivity
rates in children who have received
Infanrix hexa as primary series and as a
booster dose. Adapted from Zinke et al.
[53].
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[53] it was demonstrated that children who were administered
this vaccine as a primary series with a booster dose in the
second year of life had seroprotective/seropositive antibody
levels against all vaccine antigens up to c.6 years later with the
exception of those against PT. In particular, in these children
anti-HBsAg antibody concentrations were ≥10 IU/L in 77% and
≥100 IU/L in 33.9% of the children. Moreover, in the group of
children 7–9 years old who received a second booster dose at
5–6 years, antibody concentrations against T, FHA, PRN and
P1, P2 and P3 and those against D were found to be
seroprotective or seropositive in 100% and 98% of the cases,
respectively, showing long-term persistence of immune mem-
ory against these antigens. Unfortunately, in these children no
evaluation of anti-HBsAg antibody concentrations was per-
formed. An anamnestic response was observed in >90% of
cases in children aged 4–6 years and in those 7–9 years old
who had previously received Infanrix hexa for primary and
booster immunization when they were tested with a hepatitis
B vaccine [54,55]. Interestingly, immune memory was also
induced by previous vaccinations in children that were not
considered responders because their anti-HBsAg antibody
titres were <3.3 IU/L [55]. More than 82% of these children
had antibody concentrations ≥10 IU/L after challenge, despite
the fact that the magnitude of post-dose antibody response
was directly proportional to the antibody level before the
challenge dose and the response to the booster dose achieved
in the second year of life [55]. Because vaccination during
infancy with adequate HBsAg amount and number of doses
was found to assure protective immunity until about 20 years
of age, it seems clear that Infanrix hexa could assure long-term
protection without any further booster administration during
adolescence in immunocompetent participants. However,
several recent reports show that in some cases immune
memory could wane, indicating that some participants may
develop an increased risk of HBV infection despite adequate
vaccination during infancy [24,26]. A booster dose should be
considered for individuals who have lost immunological
memory and live in highly endemic regions where HBsAg
carriers are often positive for HBeAg [25].
Epidemiological data clearly indicate that Infanrix hexa is
protective against Hib infection. A surveillance study showed
that none of the children fully immunized with this vaccine
developed invasive Hib during a 5-year observational period
[56]. Moreover, it is believed that this preparation could be
highly protective against pertussis because it includes the same
amount of PT, FHA and PRN contained in Infanrix, a very
effective DTaP vaccine. In two studies it was demonstrated
that this vaccine was effective in ≥83.9% of the cases against
pertussis [57,58]. A 7-year follow-up of children fully vacci-
nated with Infanrix showed the incidence of pertussis reduced
to 8/100 000 person-years relative to a pre-vaccination
incidence of 225/100 000 person-years [59].
All of the studies demonstrate that Infanrix hexa is generally
well tolerated and safe in children, even in those born
prematurely and when it is co-administered with other routine
vaccines [29]. Serious adverse events were reported in <3% of
vaccine recipients and in most cases they were considered to
be unrelated to vaccine administration [33–35,60]. However,
transient and mild local and systemic adverse events were
common after vaccine administration, although the frequency
of these events was not signiﬁcantly different from comparator
vaccines. In the safety and reactogenicity report by Zepp et al.
[60], redness at the injection site was the most common
adverse event. Fever (≥38.0°C) occurred in about one-third of
children but the risk of high fever (≥39.5%) was marginal
(about 3.5%). Finally, Infanrix hexa was not associated with
SUD in the German study by von Kries et al. [27] and in a
second study [56] carried out in the same country in which the
proportion of SUDs observed in a given month and the
number of children who were given the vaccine in the same
month was evaluated. This last analysis showed that among
children receiving the vaccine in the ﬁrst year of life, the
observed number of SUDs within 14 days of vaccination was
less than the expected number of cases [56]. Similar ﬁndings
were observed in children vaccinated in the second year of life
[56].
In conclusion, Infanrix hexa has been demonstrated to be
immunogenic, effective, safe and well tolerated in children
regardless of gestational age at birth, and not signiﬁcantly
different from the vaccines used as comparators. Moreover, its
co-administration with other vaccines does not modify its
immunogenicity or reactogenicity. Its protection can be
considered similar to that offered by Hexavac for all the
diseases against which it was prepared, with the exception of
hepatitis B. Its immunogenicity seems superior to Hexavac for
hepatitis B, as demonstrated in clinical trials by the greater
seroprotection rates and higher antibody GMT shown after
the primary series, the greater booster response and the
persistence of protection until 7–9 years of age in a greater
number of children. Moreover, the high immune response
evoked in children with poor antibody production after the
primary series and booster dose after hepatitis B challenge
suggests that protection against this infection can be assured
for a signiﬁcantly longer period of time in the greatest
proportion of vaccinated immunocompetent participants. Only
poor responders or non-responders may merit a booster
dose, particularly when a participant is continuously exposed
to HBV. In addition, the presence of PRN in Infanrix hexa
offers a potential additional beneﬁt against pertussis in
comparison with Hexavac.
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Hexyon
The same pharmaceutical company that produced Hexavac has
developed a new hexavalent vaccine, Hexyon (Sanoﬁ Pasteur
MSD, Lyon, France). It has the same composition against D, T,
P, polio and Hib, but differs in hepatitis B content. Instead of
5 lg HBsAg produced from recombinant strain 2150-2-3 of
the yeast Saccharromyces cerevisiae, it includes 10 lg of HBsAg
produced in the yeast Hansenula polymorpha. Hexyon has been
evaluated in several clinical trials and is currently registered in
markets outside Europe for the primary immunization of
children from 6 weeks of age and for booster vaccination up
to 24 months of age [61,62]. It is a liquid vaccine that does not
require reconstitution of any component before injection,
facilitating administration and reducing the risk of medication
error. The immunogenicity of Hexyon used for primary
vaccination has been evaluated after three doses of the
vaccine, according to the recommended immunization sched-
ules of the countries in which the trials were conducted. In
particular, the vaccine was given at 6, 10 and 14 weeks of age
in South Africa [63], at 2, 3 and 4 months in Turkey [64] and at
2, 4 and 6 months of age in Argentina [65], Columbia, Costa
Rica [66], Mexico, Peru [67,68] and Thailand [69]. When
Hexyon was evaluated before and after booster dose, it was
administered at 15–18 months of age [64,67,70]. In all primary
series trials [64–70], Hexyon immunogenicity and safety were
compared with standard doses of licensed vaccines. Quadri-
valent, pentavalent and hexavalent vaccines were used as
comparators, with the addition of monovalent vaccines lacking
in the combined preparations. Antibody concentrations against
D, T, PT, FHA, P1, P2, P3 and Hib were generally evaluated
with the same criteria and methods previously described for
Infanrix hexa with the exception of pertussis antigens, for
which an four-fold or greater increase from baseline in
antibody concentration was predeﬁned as the surrogate
measure of seroconversion. Immune response was systemat-
ically similar to that obtained with comparators. Among the
children who had received Hexyon as a primary immunization,
the vaccine evoked seroprotective levels of antibody against D
and T in ≥95% and 100% of the cases, respectively [64–70].
Moreover, seroprotective levels against P1, P2, P3 and Hib
were reached in ≥98%, ≥95%, ≥97 and ≥91% of cases,
respectively [64–70]. Although there is a limit to the absence
of PRN, seroconversion rates for acellular pertussis antigens
were ≥90% for PT and ≥82% for FHA [64–70]. After the booster
dose, seroprotection rates with Hexyon were consistently
100% for P1, P2, P3 and Hib [64–70]. For these antigens, GMTs
of antibodies were generally higher than those following primary
immunization. Similar results were obtained for D and T,
whereas seroconversion rates for PT and FHA were ≥92% and
≥87%, respectively [64–70]. However, while GMTs for D and T
after the booster were generally higher than after the primary
series, those for PT and FHA were similar or only slightly higher
than those obtained after the priming series [64–70].
It was found that seroconversion and seroprotection rates
in response to HBSg antigen after primary series of Hexyon
were always high and not inferior to those induced by
comparators, independent of the schedule of administration.
However, as expected, children who have received a dose of
hepatitis B vaccine at birth had antibody GMT greater than
those without this prophylaxis, although the percentage of
those seroprotected was similar (>94%). Table 2 shows the
four studies in which Hexyon was compared with Infanrix
hexa for primary immunization. Two of these studies were
carried out in children who were immunized at 2, 4 and
6 months of age without any hepatitis B vaccine at birth and
without other simultaneous vaccine administration [67,71]. In
the study that enrolled the greatest number of infants (1189,
among which 1022 received the investigational vaccine and
167 Infanrix hexa), no signiﬁcant difference in the proportion
of children in whom primary immunization evoked seropro-
tective antibody levels was found (98.3% for Hexyon com-
pared with 100% for Infanrix hexa) [67]. However, the
number of children with antibody concentration ≥100 IU/L
was higher among those treated with Infanrix hexa than in
TABLE 2. Antibody response thresholds, seroconversion rates (%) and geometric mean titres (GMT) post-primary vaccination
at 2, 4 and 6 months of age and post-booster vaccination at 15–18 months of age
Authors Threshold
Hexaxim Infanrix hexa
Post-primary Pre-booster Post-booster Post-primary Pre-booster Post-booster
Aquino et al. [67] ≥10 IU/L
GMT IU/L
98.3
1142
89.8
93.3
99.4
2553
100
1576
95.4
127
100
4757
Lanata et al. [71] ≥10 IU/L
GMT IU/L
99.2
986
100
1139
Kosalaraksa et al. [69] ≥10 IU/L
GMT IU/L
99.5
2477
99.5
2442
Lopez et al. [66] ≥10 IU/L
GMT IU/L
99.7
3013
100
2766
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those receiving Hexyon (99.2% in comparison to 91.7%).
Moreover, post-primary anti-HBs GMTs were greater in
Infanrix hexa (1576 IU/L vs 1142 mIU/mL). The same ﬁndings
were observed at pre-booster and post-booster doses. Similar
data were collected in the second study, albeit with a
signiﬁcantly lower number of infants [71]. In two other
studies the two hexavalent vaccines were compared in
children who received it alongside PCV7 or PCV7 and
rotavirus vaccine and who had received a hepatitis B vaccine
at birth [66,69]. In the study by Kosalaraksa et al. [69] it was
found that the immune response to HBsAg was similar
between hexavalent vaccines and did not appear to be affected
by co-administration of other vaccines. After primary series,
99.5% of children in both groups had seroprotective antibody
concentration for anti-HBs of 98.4% and 99.5% in the Hexaxim
and in Infantix hexa groups, respectively, had antibody levels
≥100 IU/L. No modiﬁcation of immune response in compar-
ison to historical data was found. Similar results were obtained
by Lopez et al. [66] who found that infants given Hexyon were
seroprotected after primary series in 99.7% of the cases in
comparison to 100% of those who received Infanrix hexa, with
no observed interference of co-administration of PCV7 and
rotavirus vaccine. Similar antibody GMTs (3013 mIU/mL for
the investigational vaccine and 2766 for Infanrix hexa) were
detected. Persistence of seroprotection and the effect of the
administration of the booster dose were evaluated in a
number of studies with identical results. The study enrolling
the highest number of children reported that before the
booster dose seroprotection was still present in 89.8% and in
95.4% of infants included in Hexyon and Infanrix hexa groups,
respectively [67]. After the booster administration these
values increased to 99.4% and 100%.
The safety and tolerability observations of Hexyon derived
from controlled clinical studies speciﬁcally planned to evaluate
immunogenicity appear optimal. Macıas et al. [68] found that
the incidence of fever (≥39.6°C) after Hexyon was similar to
that of the comparator vaccines, lower than 5%. However, the
incidence of fever of any grade was lower following Hexyon
than after the comparator vaccine (78.4% vs 92.7%) [68]. In
general, injection-site and systemic adverse events were
similarly reported between the investigational vaccine and
comparators. When severe adverse events occurred, they
were considered unrelated to vaccine administration, with the
exception of a hypotonic–hyporesponsive episode 7 h after
the ﬁrst administration of Hexyon that was deemed possibly
related to vaccine administration [68].
In conclusion, Hexyon was deemed to be as immunogenic
as Hexavac for all antigens with the exception of HBsAg. The
increase in the amount of HBsAg content and the different
method used for its production seem to have resulted in
higher immunogenicity. However, the data available are
currently limited to the results of primary immunization and
booster dose administration. No information is available
regarding time persistence of seroprotection and the efﬁciency
of immune memory. Moreover, in an era of re-emergence of
pertussis, it is important to evaluate the real efﬁcacy of a
vaccine that includes only two pertussis antigens.
Conclusions
Hexavalent vaccines remain one of the best solutions to
increase compliance with the recommended vaccinations for
infants and children, assuring simpliﬁcation of administration
and costs. The major problem related to their use is their
efﬁcacy against hepatitis B. Hexavac was withdrawn from the
market because it could not guarantee long-term protection
against hepatitis B even in participants who were fully
vaccinated during infancy, probably because of the low HBsAg
content of the preparation. Infanrix hexa, which contains a
double amount of HBsAg, assures a long-lasting protection and
was the only hexavalent vaccine licensed for the use in
children for several years. Recently, a new hexavalent vaccine,
Hexaxim, has been developed and the ﬁrst clinical trials have
found that its immunogenicity seems to be similar to that of
Infanrix hexa. However, no long-term evaluations have been
performed and it is not known how for long the immune
memory evoked by this preparation persists. Further studies
regarding these parameters are needed. Recently collected
data seem to suggest that in some cases, immune memory can
wane regardless of the vaccine used for primary immunization.
This suggests the need for further evaluations to deﬁne which
childrens are at the highest risk and need a booster dose
during late childhood to maintain protection against hepatitis
B. Moreover, in comparison to Hexavac and Hexyon, Infanrix
hexa has the advantage of containing three pertussis antigens
(PT and FHA plus PRN). This is an additional beneﬁt that could
have an important role in the era of pertussis re-emergence.
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